“Global Pre-Filled Syringes market set to grow to $19bn by 2024” says new Visiongain report

31 January 2019
Pharma

Visiongain has launched a new pharma report Global Pre-Filled Syringes Market Forecast 2019-2029: Glass Pre-Filled Syringes, Plastic Pre-Filled Syringes, Pen Injectors and Autoinjectors, Insulin Therapies, Rheumatoid Arthritis (RA) Therapies, Growth Hormones, Vaccines, PCSK9 Inhibitors.

The pre-filled syringes market has become more competitive in recent years as both syringe component suppliers and pharma companies develop product offerings to compete with established device makers. Rapid growth in this market will be due to the increasing burden of chronic disease, the launch of new biological drugs and biosimilars and pharma companies’ need for more complex drug delivery solutions including innovative pen injectors and autoinjectors.

The lead analyst of the report commented "The market is expected to grow strongly driven by numerous trends in the overall pharmaceutical market, such as more self-administration of medicines, the development of biological drugs and biosimilars, and the increasing burden of chronic diseases such as diabetes and high cholesterol.

Innovation, suitability for use with viscous and higher-volume drugs and designing products with usability in mind will help manufacturers in this market to differentiate their products and gain market share in an increasingly competitive environment."

Leading companies featured in the report include BD, Gerresheimer, Schott, SHL Group, Ypsomed and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Clinical Trial Supply and Logistics market for pharma set to grow to $26bn by 2024” says new Visiongain report

Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs.

18 April 2019

Read

“Global Biosimilar Drugs market set to grow to $57bn by 2023” says new Visiongain report

The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature.

17 April 2019

Read

“Global Drug Discovery Outsourcing market set to grow to $45bn by 2024” says new Visiongain report

A major restraint in the global drug discovery outsourcing market comes from the fact that it is quickly becoming saturated, with many contract research organisations offering poorly differentiated services.

16 April 2019

Read

“Global Dermatological Drugs market set to grow to $36bn by 2024” says new Visiongain report

The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas.

15 April 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1